Clinical Trial Update: Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) [Phase 3]

View source ↗

Summary

Phase 3 trial of lenalidomide and dexamethasone with or without pembrolizumab in newly diagnosed multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• lenalidomide and dexamethasone with or without pembrolizumab

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2019-09-17